The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation.

The present invention is directed to compositions and methods for delivering a tissue scaffold comprising ultrasound-triggerable agents to an individual.

The present disclosure provides compositions and methods useful for tissue engineering including a composition having chemically modified RNA (cmRNA) encapsulated in or complexed with a non-viral delivery vehicle and a biocompatible, bioresorbable scaffold and methods of using the composition to regenerate, for example, bone tissue.

Provided is a slow release composition to promote bone growth, the slow release composition comprising: an oxysterol encapsulated in a biodegradable polymer to control the release of the oxysterol. Methods of making and use are further provided.

Medical devices configured to provide a controllable release of a drug, particularly for use in pleural effusion therapy. The medical devices comprise a component including a carrier-drug complex, wherein the carrier-drug complex comprises one or more molecules of a drug reversibly bound to a porous carrier. The present disclosure also relates to methods of making the carrier-drug complexes and medical devices described herein.

A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and degradation. The barrier of the present invention effectively reduces unwanted adhesions using non-synthetic components.

An implantable device for encapsulating cells includes one or more cell encapsulation layers. Each of the cell encapsulation layers includes a first membrane that is semipermeable, a second membrane that is semipermeable, and a first plurality of weld lines. The second membrane is attached to the first membrane by the first plurality of weld lines. The first membrane, the second membrane, and the first plurality of weld lines define at least one cell channel for encapsulating cells. The cell encapsulation device is configurable between a collapsed configuration and an inflated configuration.

Provided herein are compositions and methods for 3D bioprinting of mechanically strong and biologically active scaffolds using emulsion bioink for the regeneration of a wide variety of tissues with biochemical functions (e.g., bone, tendon, ligament, cartilage, etc.).

Injectable fibrous hydrogel are provided. The injectable fibrous hydrogels include a guest macromer of a hyaluronic acid (HA) backbone and host macromer of a HA backbone, the guest macromer is a HA electrospun hydrogel nanofiber functionalized with adamantane (Ad), and the host macromer is a HA electrospun hydrogel nanofiber functionalized with ?-cyclodextrin (CD). Injectable formulations that include the fibrous hydrogels are also provided, as are methods of making and using the same.

A composition containing a macrophage inhibitor may be administered in an effective amount to prevent, inhibit or reduce restenosis, thrombus or aneurysm formation in implanted polymeric vascular grafts. The composition may be administered prior to vascular graft implantation, at the same time as vascular graft implantation, following vascular graft implantation, or any combination thereof. Examplary macrophage inhibitors include bisphosphonates, anti-folate drugs and antibodies, preferably in a controlled release or liposomal formulation.